Altered levels of pro-inflammatory cytokines in sickle cell disease patients during vaso-occlusive crises and the steady state condition

European Cytokine Network

Volumn 24, Issue 1, 2013, Pages 45-52

  Keikhaei, Bijan ^a   Mohseni, Ali Reza ^b   Norouzirad, Reza ^c   Alinejadi, Mastaneh ^d   Ghanbari, Somayeh ^a   Shiravi, Fariba ^a   Solgi, Ghasem ^e  

^a AHVAZ JUNDISHAPUR UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b HIGH INSTITUTE FOR RESEARCH AND EDUCATION IN TRANSFUSION MEDICINE   (Iran)

^c DEZFUL UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d Great oil hospital   (Iran)

^e HAMADAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Cytokines; Pro inflammatory; Sickle cell anemia

Indexed keywords

HEMOGLOBIN; INTERLEUKIN 1; INTERLEUKIN 17; INTERLEUKIN 6; INTERLEUKIN 8; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE SEVERITY; ELECTROPHORESIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; SICKLE CELL ANEMIA;

CYTOKINES; PRO-INFLAMMATORY; SICKLE CELL ANEMIA;

ANEMIA, SICKLE CELL; BETA-THALASSEMIA; CASE-CONTROL STUDIES; CYTOKINES; DEMOGRAPHY; FEMALE; HUMANS; HYDROXYUREA; INFLAMMATION MEDIATORS; MALE; VASCULAR DISEASES; YOUNG ADULT;

EID: 84878098460     PISSN: 11485493     EISSN: None     Source Type: Journal    
DOI: 10.1684/ecn.2013.0328     Document Type: Article

References (40)

1. Bunn HF. Pathogenesis and treatment of sickle cell disease. N Engl J Med 1997; 337: 762-9.
2. Stuart MJ, Nagel RL. Sickle cell disease. Lancet 2004; 364: 1343-60.
3. Gee BE, Platt OS. Sickle reticulocytes adhere to VCAM-1. Blood 1995; 85: 268-74.
4. Setty BNY, Stuart MJ. Vascular cell adhesion molecule-1 is involved in mediating hypoxia-induced sickle red blood cell adherence to endothelium: Potential role in sickle cell disease. Blood 1996; 88: 2311-20.
5. Opkala I. The intriguing contribution of white blood cells to sickle cell disease: a red cell disorder. Blood Rev 2004; 18: 65-73.
6. Hebbel RP, Osarogiagbon R, Kaul D. The endothelial biology of sickle cell disease: inflammation and a chronic vasculopathy. Microcirc 2004; 11: 129-51.
7. Frenette P. Sickle cell adhesion: heterotypic, multicellular aggregations driven by leukocyte adhesion. Microcirc 2004; 11: 167-77.
8. Makis AC, Hatzimichael EC, Bourantas KL. The role of cytokine in sickle cell disease. Ann hematol 2000; 79: 407-13.
9. Pathare A, Al Kindi S, Alwan Alnaqdy A, Daar S, Knox-Macaulay H, Dennison D. Cytokine profile of sickle cell disease in Oman. Am J Hematol 2004; 77: 323-8.
10. Pathare A, Al Kindi S, Daar S, Dennison D. cytokines in sickle cell disease. Hematology 2003; 8: 329-37.
11. Ataga KI, Cappellini MD, Rachmilewitz EA. Beta thalassaemia and sickle cell anaemia as paradigms of hypercoagulability. Br J Haematol 2007; 139: 3-13.
12. Bourantas KL, Dalekos GN, Makis A, Chaidos A, Tsiara S, Mavridis A. Acute phase proteins and interleukins in steady state sickle cell disease. Eur J Haematol 1998; 61: 49-54.
13. Parise LV, Telen MJ. Erythrocyte adhesion in sickle cell disease. Curr Hematol Rep 2003; 2: 102-8.
14. Vilas-Boas W, Cerqueira BA, Zanette AM, Reis MG, Barral-Netto M, Goncalves MS. Arginase levels and their association with Th17-related cytokines, soluble adhesion molecules (sICAM-1 and sVCAM-1) and hemolysis markers among steady-state sickle cell anemia patients. Ann Hematol 2010; 89: 877-82.
15. Anyaegbu CC, Okpala IE, Aken'Ova AY, Salimonu LS. Peripheral blood neutrophil count and candidacidal activity correlate with the clinical severity of sickle cell anaemia. Eur J Haematol 1998; 60: 267-8.
16. Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease - Life expectancy and risk factors for early death. N Engl J Med 1994; 330: 1639-43.
17. Johnson C, Telen MJ. Adhesion molecules and hydroxyurea in the pathophysiology of sickle cell disease. Haematologica 2008; 93: 481-5.
18. Cajado C, Cerqueira BA, Couto FD, et al. TNF-alpha and IL-8: serum levels and gene polymorphisms (-308G>A and -251A>T) are associated with classical biomarkers and medical history in children with sickle cell anemia. Cytokine 2011; 56: 312-7.
19. Abboud MR, Taylor EC, Habib D, et al. Elevated serum and bronchoalveolar lavage fluid levels of interleukin 8 and granulocyte colony-stimulating factor associated with the acute chest syndrome in patients with sickle cell disease. Br J Haematol 2000; 111: 482-90.
20. Duits AJ, Schnog JB, Lard LR, Saleh AW, Rojer RA. Elevated IL-8 levels during sickle cell crisis. Eur J Haematol 1998; 61: 302-5.
21. Miossec P, Korn T, Kuchroo VK. Interleukin-17 and Type 17 Helper T Cells. N Engl J Med 2009; 361: 888-98.
22. Gaffen SL. An overview of IL-17 function and signaling. Cytokine 2008; 43: 402-7.
23. Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia: Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med 1995; 332: 1317-22.
24. Steinberg MH, Barton F, Castro O, et al. Effect of hydroxyurea on mortality and morbidity in adult sicklecell anemia: risks and benefits up to nine years of treatment. JAMA 2003; 289: 1645-51.
25. Maier-Redelsperger M, Labie D, Elion J. Long-term hydroxyurea treatment in young sickle cell patients. Curr Opin Hematol 1999; 6: 115-20.
26. Hankins JS, Ware RE, Rogers ZR, et al. Long-term hydroxyurea therap for infants with sickle cell anemia: the HUSOFT extension study. Blood 2005; 106: 2269-75.
27. De Montalembert M, Brousse V, Elie C, Bernaudin F, Shi J, Landais P. Long-term hydroxyurea treatment in children with sickle cell disease: tolerance and clinical outcomes. Haematologica 2006; 91: 125-8.
28. Brittain JE, Knoll CM, Ataga KI, Orringer EP, Parise LV. Fibronectin bridges monocytes and reticulocytes via integrin α4β1. Br J Haematol 2008; 141: 872-81.
29. Canalli AA, Conran N, Fattori A, Saad ST, Costa FF. Increased adhesive properties of eosinophils in sickle cell disease. Exp Hematol 2004; 32: 728-34.
30. Taylor SC, Shacks SJ, Qu Z. Invivo production of Type 1 cytokine in healthy sickle cell disease patients. J Natl Med Assoc 1999; 91: 619-24.
31. Hibbert JM, Hsu LL, Bhathena SJ, et al. Proinflammatory cytokines and the hypermetabolism of children with sickle cell disease. Exp Biol Med (Maywood) 2005; 230: 68-74.
32. Taylor SC, Shacks SJ, Qu Z. Wiley P. Type 2 cytokine serum levels in healthy sickle cell disease patients. J NatlMedAssoc 1997; 89: 753-7.
33. Gonçalves MS, Queiroz IL, Cardoso SA, et al. Interleukin 8 as a vaso-occlusive marker in Brazilian patients with sickle cell disease. Braz J Med Biol Res 2001; 34: 1309-13.
34. Michaels LA, Ohene-Frempong K, Zhao H, Douglas SD. Serum levels of substance P are elevated in patients with sickle cell disease and increase further during vaso-occlusive crisis. Blood 1998; 92: 3148-51.
35. Lard LR, Mul FP, de Haas M, Roos D, Duits AJ. Neutrophil activation in sickle cell disease. J Leukoc Biol 1999; 66: 411-5.
36. Croizat H, Nagel RL. Circulating Cytokines Response and the Level of Erythropoiesis in Sickle Cell Anemia. Am J Hematol 1999; 60: 105-15.
37. Okpala I, Daniel Y, Haynes R, Odoemene D, Goldman J. Relationship between the clinical manifestations of sickle cell disease and the expression of adhesion molecules on white blood cells. Eur J Haematol 2002; 69: 135-44.
38. Lanaro C, Franco-Penteado CF, Albuqueque DM, Saad STO, Conran N, Costa F. Altered levels of cytokines and inflammatory mediators in plasma and leukocytes of sickle cell anemia patients and effects of hydroxyurea therapy. J Leukoc Biol 2009; 85: 235-42.
39. Tavakkoli F, Nahavandi M, Wyche MQ, Perlin E. Plasma levels of TNF-alpha in sickle cell patients receiving hydroxyurea. Hematology 2004; 9: 61-4.
40. Halsey C, Roberts IA. The role of hydroxyurea in sickle cell disease. Br J Haematol 2003; 120: 177-86.